Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
TWST submitted a Rule 144 notice reporting an intended sale of 500 shares of common stock held at Fidelity Brokerage Services LLC, with a listing reference to NASDAQ and a sale-related date of 04/27/2026. The 500 shares trace to restricted stock vesting on 02/07/2024. The filing also records a prior sale of 1,000 shares by Melissa Starovasnik on 04/01/2026 for $51,000.
Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock. She exercised employee stock options to acquire 9,671 shares at an exercise price of $8.82 per share, then sold 9,671 shares in open‑market transactions at prices around $65–66 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions she directly owns 858,887 shares of Common Stock and retains employee stock options, including a grant tied to 64,950 underlying shares with a $67.85 exercise price.
TWST registration statement reports a proposed resale of 2,321 shares of Common Stock tied to restricted stock vesting on 04/22/2026 and lists prior open‑market dispositions by an affiliate, Patrick Finn, totaling multiple transactions in Jan–Feb 2026.
The filing itemizes recent sales by Patrick Finn: 2,390, 2,705, 3,500, 1,750, 68,967, and 4,294 shares on specified dates with corresponding aggregate dollar amounts. This Form 144 is a routine notice of proposed resale by an affiliate under compensation and vesting events.
Twist Bioscience (issuer) reported insider dispositions by Emily M. Leproust of Common stock on multiple dates. Transactions listed: 5,001 shares on 02/03/2026, 7,205 shares on 02/23/2026, 2,423 shares on 03/06/2026, 1,742 shares on 03/20/2026, and 1,610 shares on 04/21/2026. The filing also shows 8,061 shares described under "Securities To Be Sold" with an option grant date of 09/29/2017.
Twist Bioscience Corp submitted a Form 144 notice to sell 104,665 shares of Common Stock on 04/21/2026. The filing lists prior open-market dispositions by Emily M. Leproust totaling 16,371 shares sold on 02/03/2026, 02/23/2026, 03/06/2026, and 03/20/2026 with dollar proceeds reported for each trade.
Twist Bioscience Corp Chief Financial Officer Adam Laponis sold 4,000 shares of Common Stock in an open-market transaction. The sale occurred at a price of $60.00 per share on April 17, 2026. After this transaction, he directly holds 118,694 shares of Twist Bioscience common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Laponis previously adopted on May 8, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
TWST proposed sales of common stock by an insider under a Form 144 notice. The excerpt lists four reported transactions by Adam Laponis: 7,000 shares on 02/12/2026 for $350,000, 2,085 shares on 02/23/2026 for $97,389.93, 2,597 shares on 04/09/2026 for $129,561.48, and 3,000 shares on 04/14/2026 for $165,000. The filing also lists scheduled issuances from restricted stock vesting and an ESPP purchase on specified dates.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported an open-market sale of 3,000 shares of common stock at $55.00 per share. The transaction was made under a previously adopted Rule 10b5-1 trading plan. Following this sale, he continues to hold 122,694 shares directly.
Company filed a Form 144 disclosing proposed resale of Common Stock and recent insider sales. The filing lists three reported sales by Adam Laponis: 7,000 shares on 02/12/2026 for $350,000.00, 2,085 shares on 02/23/2026 for $97,389.93, and 2,597 shares on 04/09/2026 for $129,561.48. The notice also records recent issuances to Fidelity/employee plans: 345 shares (ESPP) and restricted stock vestings of 564 and 2,091 shares on the listed dates.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans, and were not discretionary trades. After this transaction, Laponis directly holds 125,694 shares of Twist Bioscience common stock.